Carospir (Spironolactone) Patent Expiration, LOE Window & CMS Spending
Carospir (Spironolactone) by Cmp Development: FDA Orange Book LOE 2036-10-28, 2 AB generics, $2.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Cmp Development |
| FDA Application & Pathway | N209478 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2036-10-28 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $2.7M |
| 2024 Medicare Part D Spend | $186K |
| 2024 Medicaid Spend | $2.5M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 38.2% 2-yr change) |